The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a 8.1% CAGR during the forecast period 2026 to 2035. In terms of target antigen, the CD19 targeting therapies segment holds the highest share (more than 65%) of the market. With regards to target indication, the multiple myeloma segment dominates the global market with close to 30% market share. In terms of geographical regions, North America c...

The global big data in healthcare market, valued at USD 93 billion in 2025, is projected to reach USD 110 billion in 2026 and USD 540 billion by 2035, with a 19.37% CAGR during the forecast period 2026 to 2035. The geographical regions segment highlights the distribution of big data in healthcare market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world regions. According to our projections, the big data analytic...

The global mini bioreactors market, valued at USD 1.5 billion in 2025, is projected to reach USD 1.7 billion in 2026 and USD 4.0 billion by 2035, representing a CAGR of 10.4% during the forecast period 2026 to 2035. In terms of capacity of bioreactor, the 50 mL-250 mL segment holds the highest share of the current market. Based on the type of cell culture, the mammalian culture segment holds the largest share (close to 50%) of the current market.

The global contact lenses market, valued at USD 12.7 billion in 2025, is projected to reach USD 13.2 billion in 2026 and USD 20.5 billion by 2035, representing a CAGR of 5.0% during the forecast period 2026 to 2035. Contact lenses are thin, transparent optical devices placed directly on the cornea to correct refractive errors, and are currently worn by approximately 150 million individuals worldwide. In fact, in the US alone, an estimated 45 million people use contact lenses, with 87% opting fo...

The small scale bioreactors market is estimated to grow from USD 2,479 million in 2025 to reach USD 2,739 million in 2026 and USD 5,796 million by 2035, representing a CAGR of 8.68% during the forecast period 2026 to 2035. In 2025, the batch / fed batch mode of operation dominated the market and is estimated to hold 90% of the overall revenue share by 2035. Fed batch bioreactors provide controlled nutrient environment, preventing accumulation of inhibitory byproducts that can limit cell growth....

The ultrasound market is estimated to grow from USD 9.6 billion in 2025 to reach USD 10.2 billion in 2026 and USD 16.0 billion by 2035, representing a CAGR of 5.1% during the forecast period. In May 2026, ClearPoint Neuro entered into a collaboration with Sungkyunkwan University to expand its drug delivery ecosystem. The collaboration follows successful preclinical trials demonstrating ultrasound-enabled delivery across the blood-brain barrier, aiming to accelerate commercialization and global e...

The global Fc fusion protein market, valued at USD 40.7 billion in 2025, is projected to reach USD 45.0 billion in 2026 and USD 103.7 billion by 2035, representing a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of type of fusion molecule, receptor ECD segment holds the highest share of the current market. In March 2026, Shanghai Henlius Biotech dosed the first patient in a Phase 1b/2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and...

The global nanoparticle formulation market, valued at USD 6.2 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 15.2 billion by 2035, with a CAGR of 9.3% during the forecast period 2026 to 2035. In June 2026, CEPI announced up to $9.7 million in additional funding to POP Biotechnologies to advance its SNAP nanoparticle-based vaccine platform into Phase 1 trials. The program targets rapid-response vaccines for epidemic threats such as H5N1 and Disease X, aiming to improve ant...

The E. coli fermentation market, valued at USD 7.8 billion in 2025, is projected to reach USD 8.6 billion in 2026 and USD 17.3 billion by 2035, representing a CAGR of 8.2% during the forecast period 2026 to 2035.Driven by the preference of major drug developers to retain end-to-end control over their proprietary microbial expression strains and quality control, the in-house manufacturers (~70%) dominate the E. coli fermentation market. In April 2026, WuXi Biologics achieved structural completion...

The global pulsed field ablation market, valued at USD 2.3 billion in 2025, is projected to reach USD 3.2 billion in 2026 and USD 14.6 billion by 2035, representing a CAGR of 18.4% during the forecast period 2026 to 2035. Clinical and preclinical research continues to expand the PFA evidence base, with multiple energy-delivery systems and procedural workflows under investigation. For instance, Boston Scientific’s FARAPULSE™ pulsed-field ablation (PFA) system demonstrated symptomatic relief i...

The mRNA therapeutics market, valued at USD 201 million in 2027, is projected to reach USD 2,023 million by 2030 and USD 9,988 million by 2035 (this represents the opportunity only for those mRNA therapeutics that are developed for non-COVID applications). In terms of target indication, non-small cell lung cancer is anticipated to capture the majority of the revenue share by 2035. In terms of geographical regions, North America is expected to hold largest market share by 2035. In June 2026, BioN...

The mRNA vaccines market, valued at USD 12 million in 2025, is projected to reach USD 9 million in 2026 and USD 7,047 million by 2035 (this represents the market opportunityonly for mRNA vaccines developed for non-COVID applications). In terms of target indication, the respiratory syncytial virus (RSV) infection is likely to capture the majority of the current revenue share. In terms of geographical regions, North America accounts for the largest market share, primarily due to increased research...

The global microbiome therapeutics market, valued at USD 0.5 billion in 2025, is projected to reach USD 0.6 billion in 2026 and USD 4.6 billion by 2035, representing a CAGR of 25.4% during the forecast period 2026 to 2035. With respect to route of administration, oral route dominates (around 60%) the current market. Based on the target indication, Clostridioides difficile infection captures the largest share of the current market. Amongst the therapeutic areas, gastrointestinal disorders capture...

The stem cell therapy market, valued at USD 204 million in 2025, is projected to reach USD 321 million in 2026 and USD 1,290 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. Based on end users, hospitals dominate the overall market as they possess the specialized infrastructure and expertise required to administer advanced stem cell therapies. Across key geographical regions, North America captures the largest market share owing to substantial research fundi...

The global AI in drug discovery market, valued at USD 6.0 billion in 2025, is projected to reach USD 8.6 billion in 2026 and USD 25.0 billion by 2035, representing a CAGR of 12.6% during the forecast period 2026 to 2035. In terms of application, lead optimization holds the largest share (around 50%) of the current market. With respect to the type of AI technology, machine learning dominates the current market, accounting for 40% revenue share.

The global prefilled syringes market, valued at USD 3,818 million in 2025, is projected to reach USD 4,122 million in 2026 and USD 6,750 million by 2035, representing a CAGR of 5.6% during the forecast period 2026 to 2035. In terms of therapeutic area, the market for hematological disorders is likely to capture the highest share (more than 65%) of the global prefilled syringes industry in 2026 due to the high volume of anticoagulants and blood stimulants standardized for delivery via prefilled f...

The global oral solid dosage contract manufacturing market, valued at USD 23.4 billion in 2025, is projected to reach USD 24.6 billion in 2026 and USD 39.4 billion by 2035, with a CAGR of 5.39% during the forecast period 2026 to 2035. In terms of type of finished dosage form, tablets account for the highest share (more than 70%) of the market in 2026. Based on the type of packaging, bottles are likely to occupy the largest share of the market in 2035.

The peptide therapeutics market, valued at USD 90.2 billion in 2025, is projected to reach USD 108.2 billion in 2026 and USD 233.6 billion by 2035, representing a CAGR of 8.9% during the forecast period 2026 to 2035. These therapies mimic naturally occurring biological processes and have gained widespread adoption across metabolic disorders, cancer, hormonal deficiencies, and autoimmune diseases. In recent years, the commercial success of peptide-based drugs, particularly GLP-1 receptor agonists...

The heart failure drugs market, valued at USD 7.84 billion in 2025, is projected to reach USD 9.19 billion in 2026 and USD 12.31 billion by 2035. Heart failure is a chronic condition in which the heart is unable to pump sufficient blood into different organs. Further, in order to mitigate the growing incidence, pharmaceutical companies have developed heart failure drugs that can target wide range of conditions, such as managing fluid build-up, improving cardiac contractility, controlling blood p...

The global therapeutic vaccines market, valued at USD 6.7 billion in 2025, is projected to reach USD 11.0 billion in 2026 and USD 86.8 billion by 2035, representing a CAGR of 25.8% during the forecast period 2026 to 2035. In terms of type of vaccine, the peptide vaccines segment holds the highest share (close to 45%) of the current market. Over the last few years, this segment of the industry has witnessed substantial partnership activity and investment from various private and public sector inv...